Know Cancer

or
forgot password

Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy


Phase 2
18 Years
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy


Inclusion Criteria:



- Be over age 18 years

- Be able to Communicate effectively with the study personnel

- Have histologically confirmed prostate cancer

- Have castration resistant prostate cancer patients with radiographic evidence of
metastatic disease (T any - N any - MI)

- ECOG performance status of 0 to 2

- Have been treated with ADT (chemical or surgical) for at least 6 months

- Have a castrate level of serum total testosterone (< 50ng/dL)

- Have a history of serum PSA response on ADT. A serum PSA response is an undetectable
level of serum PSA (≤ 0.2/mL) or at least a 90% reduction in serum PSA from the serum
PSA value prior to the initiation of treatment to < 10ng/mL

- Have a rising serum PSA on two successive assessments at least 2 weeks apart and
serum PSA levels ≥ 2ng/mL or > 2 ng/mL and a 25% increase above the nadir from the
ADT.

- Be continued on ADT throughout this study

- give written informed consent prior to any study specific procedures

- subjects must agree, if not already on anticoagulation therapy or aspirin, to take 81
mg aspirin daily throughout the duration of their participation in this study and for
30 days after completion of dosing with GTx-758.

- Subjects must agree to use acceptable methods of contraception:

- If their female partners are pregnant or lactating, acceptable methods of
contraception from the time of the first administration of study medication until 3
months following administration of the last dose of study medication must be used.
Acceptable methods are: condom used with spermicidal foam/gel/film/cream/suppository.
If the subject has undergone surgical sterilization (vasectomy with documentation of
azospermia), a condom with spermicidal foam/gel/film/cream/suppository should be
used.

- If the male subject's partner could become pregnant, use acceptable methods of
contraception from the time of the first administration of study medication until 3
months following administration of the last dose of study medication.Acceptable
methods of contraception are as follows: condom with spermicidal
foam/gel/film/cream/suppository [i.e., barrier method of contraception], surgical
sterilization (vasectomy with documentation of azospermia) and a barrier method
{condom used with spermicidal foam/gel/fil/cream/suppository}, the female partner
uses oral contraceptives (combination estrogen/progesterone pills), injectable
progesterone or subdermal implants and a barrier method {condom used with spermicidal
foam/gel/film/cream/suppository}.

- If the female partner has undergone documented tubal ligation (female sterilization),
a barrier method {condom used with spermicidal foam/gel/film/cream/suppository}
should be used

- If the female partner has undergone documented placement of an intrauterine device
(IUD) or intrauterine system (IUS), a barrier method {condom with spermicidal
foam/gel/film/cream/suppository} should also be used.

Exclusion Criteria:

- Known hypersensitivity or allergy to estrogen or estrogen like drugs

- Need for urgent chemotherapy, radiation therapy or surgical intervention for prostate
cancer in the opinion of the investigator;

- Any disease or condition (medical or surgical) which might compromise the
hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic,
or central nervous system; or other conditions that may interfere with the
absorption, distribution, metabolism or excretion of study drug, or would place the
subject at increased risk

- Subjects with a personal history of abnormal blood clotting or thrombotic disease
(venous or arterial thrombotic events such as history of stroke, deep vein thrombosis
(DVT), and or pulmonary embolus (PE)).

- Any subjects, as determined by a central laboratory, with

1. a modified activated protein C reaction ratio ≤ 2.5 and a Factor V Leiden gene
mutation,

2. an antithrombin level below the lower limit of the normal range,

3. a serum homocystine level exceeding the upper limit of the normal range

4. an antiphospholipid antibody level that is indeterminate, positive, or outside
the normal range,

5. or a prothrombin gene mutation

- Symptomatic congestive heart failure (NYHA Class III - IV), unstable angina pectoris,
cardiac arrhythmia, or history of atrial fibrillation

- The presence of consistently abnormal laboratory values which are considered
clinically significant. In addition, any subject with liver enzymes (ALT or AST)
above 2 times the upper limit of normal, total bilirubin above 2 times the upper
limit of normal, or serum creatinine above 1.5 times the upper limit of normal will
NOT be admitted to the study.

- Received an investigational drug within a period of 90 days prior to the enrollment
in the study.

- Received the study medication GTx-758 previously;

- Currently taking testosterone, testosterone like agents, 5a-reductase inhibitor
(finasteride, dutasteride),or antiandrogens (bicalutamide, flutamide or nilutamide).
Subjects taking a 5a-reductase inhibitor or one of these antiandrogens may be
eligible if the subject undergoes a 6 week washout period after stopping therapy. The
subject must have at least two rising serum PSA levels at least 2 weeks apart after
therapy with these 5a-reductase inhibitor or these antiandrogens have been stopped
(antiandrogen withdrawal)and complete the 6-week washout period to be eligible;

- Have previously taken or are currently taking diethylstilbestrol, other estrogens,
abiraterone or ketoconazole or any other inhibitor of CYP17
(17a-hydroxylase/C17,20-lyase);

- Currently having radiation therapy to prostate for cancer control (radiation to bone
to relieve pain is acceptable)

- Have previously taken or are currently taking enzalutamide;

- Have previously received cytotoxic chemotherapy for prostate cancer;

- Recent hospitalization (within 30 days of screening);

- Recent surgery (within 30 days of screening);

- Have taken body building or fertility supplements within 4 weeks of admission into
the study;

- Have been previously diagnosed or treated for active cancer (other than prostate
cancer or non-melanoma skin cancer)within the previous five years;

- Have a BMI > 35.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Decline in Serum PSA

Outcome Description:

The proportion of subjects with a 50% decline from baseline in serum PSA (confirmed by a second serum PSA assessment 30 days later) by Day 90 (with follow up confirmation by Day 120)

Outcome Time Frame:

120 days

Safety Issue:

No

Principal Investigator

Domingo Rodriguez, MD

Investigator Role:

Study Director

Investigator Affiliation:

GTx

Authority:

United States: Food and Drug Administration

Study ID:

G200712

NCT ID:

NCT01615120

Start Date:

July 2012

Completion Date:

October 2014

Related Keywords:

  • Prostate Cancer
  • Prostatic Neoplasms

Name

Location

West ClinicMemphis, Tennessee  38117
Connecticut Clinical Research CenterWaterbury, Connecticut  06708-2652
The Urology GroupCincinnati, Ohio  45212
Urology of IndianaIndianapolis, Indiana  46254
Pinellas UrologySt. Petersburg, Florida  33710
Seattle Cancer Care Alliance, Univ. of WashingtonSeattle, Washington  98109
Urology Associates Medical GroupBurbank, California  91505
Five Valleys UrologyMissoula, Montana  59802
Urology of VirginiaNewport News, Virginia  23606
Tower UrologyLos Angeles, California  90048
Carolina Clinical TrialsConcord, North Carolina  28025
First Urology PSCJeffersonville, Indiana  47130
GTx Investigative SiteAventura, Florida  33180
Coastal Medical CenterSarasota, Florida  34237
Clinical Trials of ArizonaGlendale, Arizona  85306
VA of Greater Los AngelesLos Angeles, California  90073
San Bernardino Urological Assoc.San Bernardino, California  92404
Genesis Healthcare PartnersSan Diego, California  92123
Urology Specialists of So. CaliforniaTorrance, California  90505
Univ. of Colorado Cancer CenterAurora, Colorado  80045
So. Florida Medical ResearchAventura, Florida  33180
AMPM ResearchMiami, Florida  33145
Chesapeake Urology Research Assoc.Towson, Maryland  21204
Urological Institute of NE New YorkAlbany, New York  12208
AMP of NYOneida, New York  13421
UCSEPABala Cynwyd, Pennsylvania  19004